The Industry & Academic Cooperation in Chungnam National University (iac)

Articure, Inc.

Inje University

Moonkyung Kang

Soojin Kim

Yeon-Soo Kim

Yeon Soo Kim

Young-Kwan Lee

Hyojeong Hong

In Seop So

Min Jeong Baek

Jongpil Kim

Disclosed is a gene therapy vector in which the occurrence of recombination is minimized. In order to minimize the occurrence of recombination, which is a major problem in the production and infection of a retroviral vector virus that continuously expresses a therapeutic gene during virus replication, a cleaved MCMV promoter was prepared by cutting the MCMV promoter on the basis of a repeat sequence, and the cleaved MCMV promoter was introduced to prepare a vector. It was confirmed that the vector having the cleaved MCMV promoter incorporated therein does not cause recombinations even after being incubated multiple times, and shows a continuous expression of the therapeutic protein, and in cells transfected with the virus containing the vector, cell death effectively occurs when a prodrug is administered thereto. Accordingly, the vector with minimized recombination occurrence of the present invention can be advantageously used for the treatment of cancer.

Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus

The present invention relates to a replication retrovirus vector system comprising thymidine kinase (HSV-TK) gene and cytosine deaminase (CD) gene which make gene transfer to cancer cell tissue for the efficient treatment of cancer. Particularly, the HSV-TK/CD combined self-replicating retrovirus vector system of the present invention characteristically contains both HSV-TK and CD genes; has no worries about losing a therapeutic gene because recombination does not occur in this system during virus infection; and has an excellent stability, and also is able to induce cancer cell death by using the prodrug GCV or 5-FC and can apply a therapeutic gene or a prodrug thereof selectively to such cancer that shows resistance against cancer treatment using either TK or CD, so that this system of the invention can be advantageously used as a pharmaceutical composition for the treatment of cancer.

Gene therapy vector system and prodrug genes

The inventive chimeric ligand in the form of a fusion polypeptide of a single-chain antibody specific for Tag-72 surface antigen and GaLV envelope glycoprotein shows high transduction efficiency to cancer cells, specifically infects target cells and efficiently delivers a therapeutic gene. Accordingly, the inventive chimeric ligand can be effectively used for gene therapy to inhibit tumor growth and metastasis.

Cancer cell targeting gene delivery method

Growing community of inventors

Daejeon, South Korea

Moonkyung Kang